Skip to main content

Contineum Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

CTNM$10.30+8.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

Page
PART I. · FINANCIAL INFORMATION
Item 1.Condensed Financial Statements (Unaudited)1
Condensed Balance Sheets1
Condensed Statements of Operations and Comprehensive Loss2
Condensed Statements of Stockholders’ Equity3
Condensed Statements of Cash Flows4
Notes to Unaudited Condensed Financial Statements5
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations16
Item 3.Quantitative and Qualitative Disclosures About Market Risk27
Item 4.Controls and Procedures27
PART II.OTHER INFORMATION
Item 1.Legal Proceedings28
Item 1A.Risk Factors28
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds83
Item 3.Defaults Upon Senior Securities83
Item 4.Mine Safety Disclosures83
Item 5.Other Information83
Item 6.Exhibits85
Signatures86
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.